

Food & Function

Accepted Manuscript



This is an *Accepted Manuscript*, which has been through the Royal Society of Chemistry peer review process and has been accepted for publication.

Accepted Manuscripts are published online shortly after acceptance, before technical editing, formatting and proof reading. Using this free service, authors can make their results available to the community, in citable form, before we publish the edited article. We will replace this *Accepted Manuscript* with the edited and formatted *Advance Article* as soon as it is available.

You can find more information about *Accepted Manuscripts* in the [Information for Authors](#).

Please note that technical editing may introduce minor changes to the text and/or graphics, which may alter content. The journal's standard [Terms & Conditions](#) and the [Ethical guidelines](#) still apply. In no event shall the Royal Society of Chemistry be held responsible for any errors or omissions in this *Accepted Manuscript* or any consequences arising from the use of any information it contains.

1 *Original research paper*

2

3 Protective effects of *Drynaria fortunei* against 6-hydroxydopamine-induced oxidative
4 damage in B35 cells via PI3K/AKT pathway

5

6 Hui-Chun Kuo ^{a,†}, Hung-Chi Chang ^{b,†}, Wan-Cheng Lan ^a, Fan-Hsuan Tsai ^c,

7 Jung-Chun Liao ^{d,*} and Chi-Rei Wu ^{a,*}

8

9 **Affiliation**

10 ^a *The Department of Chinese Pharmaceutical Sciences and Chinese Medicine*

11 *Resources, College of Pharmacy, China Medical University, No.91, Hsueh Shih Road,*

12 *Taichung, 40402, Taiwan, R.O.C.*

13 ^b *Department of Golden-Ager Industry Management, College of Management,*

14 *Chaoyang University of Technology*

15 ^c *The School of Chinese Medicines for Post-Baccalaureate, I-Shou University, No.8,*

16 *Yida Rd., Yanchao Township, Kaohsiung County 82445, Taiwan, R.O.C.*

17 ^d *The School of Pharmacy, College of Pharmacy, China Medical University, No.91,*

18 *Hsueh Shih Road, Taichung, 40402, Taiwan, R.O.C.*

19

20 **Correspondence**

21 Dr. Chi-Rei Wu, The School of Chinese Pharmaceutical Sciences and Chinese

22 Medicine Resources, College of Pharmacy, China Medical University, 91, Hsueh Shih

23 Road, Taichung, 40402, Taiwan, R.O.C. E-mail: crw@mail.cmu.edu.tw Phone: + 886

24 4 22053366 5506

25 [†] Both authors contribute equally

26

27 **Abstract**

28 In this study, we demonstrated the antioxidant and protective properties of aqueous
29 extract of two commercial Polypodiaceae plants - *Drynaria fortunei* (DF) and
30 *Pseudodrynaria coronans* (PC) against 6-hydroxydopamine (6-OHDA)-induced
31 oxidative damage in B35 neuroblastoma cells. The contents of their phytochemical
32 profiles were determined by spectrophotometric methods and high performance liquid
33 chromatography using a photodiode array detector. DF extract has better effects than
34 PC extract in scavenging ROS and inhibiting 6-OHDA autoxidation. Following
35 exposure of B35 cells to 6-OHDA, there was a marked decrease in cell survival and
36 the activation of intracellular antioxidant enzymes and PI3K/AKT pathway, and then
37 the level of lipid peroxidation was increased. Pretreatment with DF extract blocked
38 these 6-OHDA-induced cellular events. Naringin and epicatechin are major
39 components of DF extract. These results show that DF extract exerts the protective
40 effects against 6-OHDA toxicity *via* radical scavenging activity and the increase in
41 the activation of PI3K/AKT pathway to elevate the levels of intracellular antioxidant
42 enzymes including HO-1, NQO-1 and glutathione-related enzymes.

43

44 **Keywords:** *Drynaria fortunei*; naringin; antioxidant activity; 6-hydroxydopamine;

45 PI3K/AKT; HO-1

46

47 **Introduction**

48 The rhizome of *Drynaria fortunei* (Kunze) J. Smith (Polydiaceae) (DF) is a major
49 resource for the traditional Chinese medicine “Gu-Sui-Bu” in China, which is used to
50 prevent osteoporosis and aging-associated symptoms. Accumulating evidence shows
51 that DF has osteoprotective effects through its osteogenic differentiating and
52 proliferating activities in cell culture and animal studies.¹⁻⁴ Flavonoids and
53 phenylpropanoids, such as epicatechin, naringin and neoeriocitrin, are the active
54 constituents of DF extract for its osteoprotective activities.¹⁻⁴ Other pharmacological
55 studies indicate that DF has antioxidant and anti-apoptotic activities.^{5,6} The above
56 phytoconstituents also have neuroprotective and anti-apoptotic activities through their
57 antioxidant mechanisms *in vitro* and *in vivo*.⁷⁻¹⁰ The rhizome of *Pseudodrynaria*
58 *coronans* (Wall.) Ching (Polydiaceae) (PC) is an alternative medicinal resource for
59 “Gu-Sui-Bu” in Taiwan. There are no phytochemical and pharmacological reports on
60 PC. Therefore, this investigation is first that is aimed at comparing the
61 phytoconstituents and reactive oxygen species (ROS) scavenging activities of two
62 commercial “Gu-Sui-Bu” resource plants, DF and PC, because ROS are major
63 intermediate neurotoxins and play an important role in intracellular oxidative damage
64 due to aging-associated disorders.

65 Natural antioxidants, including flavonoids and phenylpropanoids, scavenge free
66 radicals, which initiate and propagate oxidative chain reactions, thus, prevent
67 intracellular oxidative damage.¹¹ Intracellular oxidative stress cascades, including
68 biomolecules, act through ROS and deficient intracellular antioxidant defenses, which
69 might induce the aging process and aging-associated neurodegenerative diseases such
70 as Alzheimer’s disease (AD) and Parkinson’s disease (PD).^{12, 13} One of major
71 pathological mechanisms in PD is autoxidation and enzymatic oxidation of dopamine

72 in the substantia nigra, which causes selective apoptosis and a loss of dopaminergic
73 neurons.¹⁴ 6-hydroxydopamine (6-OHDA) is a toxic oxidative dopamine metabolite
74 that is rapidly and non-enzymatically oxidized by molecular oxygen to form
75 *p*-quinone and ROS, such as superoxide anion and hydrogen peroxide, under
76 physiological conditions.¹⁵ Thus, 6-OHDA is a widely used compound for
77 investigating pathogenesis and progression of as well as drug development for PD.
78 Therefore, we further attempted to demonstrate the role of intracellular antioxidants
79 and protective enzymes on the protective effects of DF extract against
80 6-OHDA-induced neuronal damage in B35 neuroblastoma cells because neuronal
81 cells have several antioxidants and protective enzymes to prevent ROS formation or
82 detoxify ROS.¹⁶

83

84 **Materials and methods**

85 **Preparation of the herb extracts**

86 Two Polydiaceae plants (DF and PC) were identified and provided by Hung-Chi
87 Chang. DF or PC was extracted with distilled water, and the resulting extract was
88 concentrated under reduced pressure to obtain DF or PC extract.⁶ To assess
89 phytoconstituents and ROS-scavenging activities, the DF or PC extract was dissolved
90 in distilled water. To clarify the protective effects from and mechanism for
91 6-OHDA-induced neuronal damage, the DF or PC extract stock solutions were
92 prepared using sterile distilled water, filtered using a 0.22 μ M sterile filter and then
93 diluted with DMEM without phenol red.

94

95 **Chemicals**

96 2-deoxyribose, 3-(2-pyridyl)-5,6-diphenyl-1,2,4-triazine-4',4''-disulfonic acid
97 (ferrozine), 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium (MTT),
98 5,5'-dithio-bis(2-nitrobenzoic) acid (DTNB),
99 6-hydroxy-2,5,7,8-tetramethyl-chroman-2-carboxylic acid (trolox), 6-OHDA, ascorbic
100 acid, (+)-catechin, cyanidin, epicatechin, ferrous sulfate heptahydrate,
101 Folin-Ciocalteu's reagent, reduced glutathione (GSH), glutathione peroxidase (GPx),
102 glutathione reductase (GR), homovanillic acid (HVA), horseradish peroxidase
103 (HRPase), malodialdehyde (MDA), naringin, nitroblue tetrazolium chloride (NBT),
104 quercetin, sodium carbonate, sodium molybdate, sodium nitrate, superoxide dismutase
105 (SOD), thiobarbituric acid (TBA), trichloroacetic acid (TCA), verbascoside, xanthine
106 and xanthine oxidase were purchased from Sigma-Aldrich Chem. Corp. (St. Louis,
107 MO, USA). Hydrogen peroxide (H₂O₂) and all HPLC-grade solvents were purchased
108 from Merck (Darmstadt, Germany).

109

110 **Determination of phytoconstituents using a spectrophotometric reader**

111 The levels of all phytochemicals, including total phenol, phenylpropanoid,
112 flavonols and anthocyanidins, were assayed using a 96-well microtiter
113 spectrophotometric method. The method used to determine the total phenolic levels is
114 based on forming blue-colored products through a redox reaction with
115 Folin-Ciocalteu's reagent and measuring its absorbance at 725 nm. The total phenolic
116 concentration of the samples was expressed as mg of catechin equivalents per gram of
117 sample¹⁷. The method used to determine total phenylpropanoid levels is based on
118 forming colored products using phenylpropanoid with the Arnow reagent (containing
119 5% (w/v) sodium nitrate and 5% sodium molybdate) and measuring its absorbance at
120 525 nm. The total phenylpropanoid concentration of the samples was expressed as mg

121 of verbascoside equivalents per g of sample.¹⁷ The method used to determine
122 flavonols and anthocyanidin levels is based on switching the absorbance wavelength
123 through different hydrogen chloride concentration and measuring its absorbance at
124 360 and 520 nm.¹⁸

125

126 **Determination of phytoconstituents using high performance liquid**
127 **chromatography (HPLC)**

128 Aqueous DF or PC extract was dissolved in distilled water and then filtered using a
129 0.22 µm filter. Stock solutions of the standards were prepared in methanol to the final
130 concentration 10 mg/mL. All standard and sample solutions were injected into 10 µL
131 in triplicate. The Shimadzu VP series HPLC and Shimadzu Class-VPTM
132 chromatography data systems were used. All chromatographic operations were
133 performed at 25 °C. The epicatechin and naringin chromatographic peaks were
134 confirmed by comparing their retention times and UV spectra. A LiChrospher®
135 RP-18e (250 × 4 mm, 5 µm) column (Merck KGaA, Darmstadt, Germany) was used.
136 Certain separating conditions including the mobile phases and gradient program
137 conditions, followed the description by Liu et al.¹⁹

138

139 **Determination of ROS using scavenging activity assay *in vitro***

140 The superoxide anion, H₂O₂ and hydroxyl radical scavenging activities were
141 determined as described previously.¹⁷ The superoxide anion scavenging activity is
142 based on the reaction between NBT and the superoxide anion produced from xanthine
143 and xanthine oxidase and was determined at 560 nm for 5-min kinetics using a
144 microplate reader (PowerWave_x, Bio-Tek instruments, Inc., Winooski, VT, USA).
145 The results were expressed as the U of SOD equivalents per milligram of sample. The

146 H₂O₂ scavenging activity is based on HVA dimer formation through the reaction
147 between H₂O₂ and HVA catalyzed by HRPase, which was measured by the
148 fluorescence intensity at the excitation 315 nm and emission 425 nm using a
149 fluorescence microplate reader (FLX800, Bio-Tek instruments, Inc., Winooski, VT,
150 USA). The H₂O₂ scavenging activity results were expressed as μ mol of trolox
151 equivalents per gram of sample. The hydroxyl radical scavenging activity was
152 monitored at 532 nm using the 2-deoxyribose-TBARS method. The hydroxyl radical
153 scavenging activity results were expressed as mg of quercetin equivalents per gram of
154 sample.

155

156 ***In vitro* lipid peroxidation inhibition assay**

157 The whole rat brain was homogenized (100 mg/mL) in ice-cold 0.1 M phosphate
158 buffer (pH 7.4), and then brain homogenate was centrifuged at 10,000 rpm for 15 min
159 at 4 °C. The reaction mixture consisted of brain homogenate, 1 mM ferrous sulfate, 5
160 mM ascorbic acid and sample solution. The reaction solution was incubated at 37 °C
161 for 30 min, and the thiobarbituric acid reactive substance (TBARS) test was
162 performed by rapidly adding 1.2% (w/v) TBA and 10% TCA. The TBARS test tubes
163 were incubated at 90 °C for 60 min, cooled, and centrifuged at 3,000 rpm for 10 min;
164 the absorbance of the supernatant was then determined at 532 nm.¹⁷

165

166 ***In vitro* ferric ion reducing antioxidant power (FRAP) assay**

167 Briefly, 25 μ L of sample solution or trolox standards were mixed with 25 μ L of
168 freshly prepared FRAP reagent, which consisted of 10 mM
169 2,4,6-tri(2-pyridyl)-s-triazine (TPTZ) solution in 40 mM HCl, 20 mM FeCl₃, and 50
170 mM acetate buffer (pH 3.6). The reaction mixture absorption was measured at 595 nm.

171 The results were calculated based on a standard curve obtained using trolox and
172 expressed as the relative trolox equivalent per gram of sample.¹⁷

173

174 ***In vitro* iron-chelating activity (ICA) assay**

175 This method is based on ferrozine-Fe⁺² colored complex formation, and the
176 absorbance is measured at 562 nm. The percentage of inhibition of ferrozine-Fe⁺²
177 complex formation was calculated as we previously reported.¹⁷

178

179 **Inhibition of 6-OHDA autoxidation *in vitro***

180 Autoxidation of 6-OHDA was followed spectrophotometrically by monitoring
181 *p*-quinone formation at 490 nm.²⁰ The assay was conducted in a cell free system under
182 conditions that correspond to cellular 6-OHDA treatments. Stock solutions of
183 6-OHDA (100 mM) were prepared in phosphate-buffered saline solution. The
184 experiment was initiated by adding 6-OHDA to yield the final concentration 50 μM.
185 The absorbance at 490 nm was monitored for 3 min at 30-sec intervals at 37°C

186

187 **The protective effects of 6-OHDA-induced neuronal damage in B35 cells**

188 Rat B35 neuroblastoma cells were cultured in DMEM supplemented with 10%
189 fetal bovine serum, 100 units/mL penicillin and 100 μg/mL streptomycin in a
190 water-saturated atmosphere with 5% CO₂ at 37 °C. The experiments were performed
191 24 h after the cells were seeded in 96-well sterile clear-bottom plates or a 90-mm dish.
192 The cells were plated at an appropriate density according to the scale of each
193 experiment. The DF or PC extract was treated 1 h before 6-OHDA (50 μM) was
194 added. 6-OHDA (50 μM) was used after a 24-h exposure, as described below. B35
195 neuroblastoma cells were seeded in a 90-mm dish and incubated overnight in a

196 water-saturated atmosphere with 5% CO₂ at 37°C. The cell morphology was observed
197 24 h after 6-OHDA exposure using a phase-contrast microscope (Nikon, Tokyo,
198 Japan).

199 The MTT assay is based on the ability of living cells to reduce MTT to insoluble
200 formazan, which is measured at 570 nm to study cell survival as we previously
201 reported.²¹ Briefly, 24 h after 6-OHDA exposure, the medium was replaced and MTT
202 was added to each well. After incubating for 2 h at 37°C, the cells were washed with
203 PBS, and DMSO was added. The experiments were performed in triplicate over four
204 independent experiments. Cell viability was expressed as the percentage relative to
205 untreated cells, which served as the control group (designated 100% viable).

206

207 **Intracellular antioxidant enzyme and GSH level measurements**

208 Following incubation for 24 h with 6-OHDA, B35 neuroblastoma cells were
209 collected from culture dishes and sonicated on ice. The solution was centrifuged for
210 15 min at 4°C to eliminate cell debris, and the supernatant was used in enzyme
211 activity assays. The antioxidant enzyme activities, including for GPx and GR, were
212 measured as we previously reported.²¹ The GPx and GR activities were expressed as
213 mU/mg of protein. The GSH levels were determined described previously.²¹ Briefly,
214 the lysates (20 µg/50 µL) or GSH standard was pipetted into each well of a 96-well
215 plate. The reaction solution, included DTNB, NADPH and GR, was added to each
216 well and was recorded at 405 nm for 5 min in a microplate reader. The GSH levels
217 were expressed as pmol/mg of protein.

218

219 **The lipid peroxidation assay in B35 cells**

220 Lipid peroxidation was measured using the TBARS assay in cell cultures. Briefly
221 the lysates (200 $\mu\text{g}/100 \mu\text{L}$) or MDA standard was pipetted into 1.5 mL tubes, and a
222 TBA test was performed. Next, the supernatant absorbance at 532 nm was
223 determined.²¹ The experiments were performed in triplicate over three independent
224 trials. The MDA levels were expressed as nmol/mg of protein.

225

226 **Western blot analysis**

227 Twenty-four hours after 6-OHDA exposure, the cells were subjected to western
228 blot analyses to determinate of the levels of phosphoinositide 3-kinase (PI3K)/AKT
229 pathway, heme oxygenase-1 (HO-1) and NAD(P)H:quinone oxidoreductase (NQO-1).
230 Briefly, the protein samples were extracted from the cell and quantified using a
231 Bradford protein assay kit (Bio-Rad), followed by electrophoretic separation through
232 SDS-PAGE. After transferring the protein samples to PVDF membranes, the samples
233 were incubated with primary antibodies against PI3K, AKT, phospho-AKT (serine
234 473) (*p*-AKT (ser)), phospho-AKT (threonine 308) (*p*-AKT (thr)), HO-1 or NQO-1,
235 overnight at 4 °C and subsequently incubated with horseradish peroxidase-conjugated
236 goat anti-rabbit or goat anti-mouse IgG. The images were scanned using an LAS-4000
237 mini imaging system (Fujifilm, Kanagawa, Japan), and the optical density data were
238 analyzed using MultiGauge v3.0 software (Fujifilm, Kanagawa, Japan). For the
239 western blot analyses, β -actin served as an internal control.

240

241 **Statistical Analyses**

242 All results were expressed as the mean \pm standard deviation (SD). The significant
243 differences were calculated using SPSS software with a one-way ANOVA followed
244 by Scheffe's test, and P values < 0.05 were considered significant.

245

246 **Results**

247 **DF or PC extract phytoconstituents**

248 The levels of total phenols, flavonoids, phenylpropanoids and anthocyanidins in the
249 DF or PC extract were measured using 96-well microtiter spectrophotometric methods
250 and are shown in **Table 1**. The levels of total phenols, flavonoids, phenylpropanoids
251 and anthocyanidins in each gram of DF extract were equivalent to 268.41 mg catechin,
252 13.67 mg quercetin, 21.05 mg verbascoside and 2.07 mg cyanidin. However, the
253 levels of total phenols, flavonoids, phenylpropanoids and anthocyanidins in each gram
254 of PC extract were equivalent to 130.10 mg catechin, 7.42 mg quercetin, 4.50 mg
255 verbascoside and 1.22 mg cyanidin.

256 The phytoconstituents of the DF or PC extract were further assayed using high
257 performance liquid chromatography. Their chromatographs are shown in **Figure 1**;
258 the certain phytoconstituent peak zones differ between the DF and PC extracts. Each
259 gram of DF extract contained 26.23 mg of naringin and 1.00 mg of epicatechin. Each
260 gram of PC extract contained 10.27 mg of naringin and 1.46 mg of epicatechin (**Table**
261 **1**).

262

263 **The ROS-scavenging and lipid peroxidation inhibiting activities of DF or PC**

264 **extract *in vitro***

265 The scavenging activity of DF or PC extract against ROS was also investigated
266 using 96-well microtiter spectrophotometric methods. The scavenging activity of each
267 gram of DF extract against superoxide anion, H₂O₂ and hydroxyl radical was
268 equivalent to 11.46 U of SOD, 927.57 μmol of trolox and 14.95 mg of quercetin. The
269 scavenging activity of each gram of PC extract was equivalent to 9.43 U of SOD,

270 582.60 μmol of trolox and 4.40 mg of quercetin (**Table 2**). Next, their lipid
271 peroxidation-inhibiting effects were evaluated using the Fe^{2+} /ascorbate method, for
272 which rat brain homogenate was used as the oxidizable biomolecule target. The IC_{50}
273 of DF extract against lipid peroxidation is 32.43 mg/mL and the IC_{50} of PC extract is
274 117.99 mg/mL (**Table 2**). Furthermore, their iron-chelating and reducing power
275 activities were further investigated using 96-well microtiter spectrophotometric
276 methods (ICA and FRAP tests). The reducing power of each gram of DF extract is
277 equivalent to 1034.65 μmol of trolox and better than that of PC extract (each gram is
278 equivalent to 622.64 μmol trolox) (**Table 2**). However, the above extracts did not
279 have iron-chelating capacities at the concentrations used in the hydroxyl radical
280 scavenging and lipid peroxidation-inhibiting assays (data not shown).

281

282 **DF or PC extract inhibits 6-OHDA autoxidation *in vitro***

283 The DF or PC extract inhibiting activity against *p*-quinone production from
284 6-OHDA autoxidation under cell-free physiological conditions was also investigated
285 through 96-well microtiter spectrophotometric methods. The reaction mixture (only
286 6-OHDA) absorbance at 490 nm was considered 100% of *p*-quinone produced from
287 6-OHDA. The DF extract at 25 - 250 $\mu\text{g/mL}$ inhibited absorbance at 490 nm in a
288 concentration-dependent manner ($P < 0.05$, $P < 0.001$). The PC extract at only 50 -
289 250 $\mu\text{g/mL}$ inhibited absorbance at 490 nm ($P < 0.05$, $P < 0.01$) (**Figure 2**)

290

291 **The protective effects of the DF extract against 6-OHDA-induced neuronal** 292 **damage in B35 neuroblastoma cells**

293 We further evaluated the protective effects of DF extract at 10 - 250 $\mu\text{g/mL}$ against
294 6-OHDA-induced neuronal damage in B35 neuroblastoma cells using the MTT assay.

295 Incubation with 50 μ M 6-OHDA to B35 neuroblastoma cells for 24 h, cell viability
296 was decreased to 46.3% compared with the control ($P < 0.001$) (**Fig. 3(A)**). The DF
297 extract at 50 - 250 μ g/mL increased the cell viability against 6-OHDA in a
298 concentration-dependent manner ($P < 0.01$, $P < 0.001$) (**Fig. 3(A)**). Furthermore, we
299 observed morphological alterations of B35 neuroblastoma cells through
300 phase-contrast microscopy. Incubation with 50 μ M 6-OHDA for 24 h decreased the
301 cell number and cell shrinkage (**Figure 3(B)-a and 3(B)-b**). The DF extract (50 - 100
302 μ g/mL) attenuated the morphological changes (**Figure 3(B)-c and 3(B)-d**).

303

304 **GSH cycle involvement in the protective effects of DF extract**

305 To clarify the protective mechanism of the DF extract against 6-OHDA-induced
306 neuronal damage in B35 neuroblastoma cells, we measured the intracellular
307 antioxidant defenses including the levels of GSH and related antioxidant enzymes
308 activities. The intracellular GSH levels as well as GPx and GR activities in B35
309 neuroblastoma cells treated with 50 μ M 6-OHDA for 24 h were lower ($P < 0.01$)
310 (**Table 3**). The level of MDA in B35 neuroblastoma cells treated with 50 μ M
311 6-OHDA for 24 h was greater ($P < 0.01$) (**Table 3**). The DF extract at 100 μ g/mL
312 partially restored the intracellular GSH levels, and partially reversed the decrease in
313 activities of GPx and GR by 50 μ M 6-OHDA in B35 neuroblastoma cells ($P < 0.05$)
314 (**Table 3**). The DF extract at 100 μ g/mL also decreased the level of MDA, which was
315 increased by 6-OHDA ($P < 0.05$) (**Table 3**).

316

317 **Reversal of PI3K/AKT-, NQO-1- and HO-1-mediated damage through the** 318 **protective effects of DF extract**

319 Because neuronal damage due to 6-OHDA mainly occurs through the PI3K/AKT
320 pathway and a decrease in detoxifying enzymes such as HO-1 and NQO-1,^{32, 33} we
321 assayed the levels of PI3K/AKT pathway proteins, HO-1 and NQO-1 in B35
322 neuroblastoma cells treated with 6-OHDA and DF extract. The protein immunoblot
323 assay is shown in **Figure 4(A)**. 6-OHDA decreased the levels of PI3K ($P < 0.01$) but
324 did not alter the level of AKT ($P > 0.05$) (**Figure 4(B)** and **Figure 4(C)**). However,
325 6-OHDA decreased the ratio of *p*-AKT (thr) to AKT and *p*-AKT (ser) to AKT ($P <$
326 0.001) (**Figure 4(D)**, **Figure 4(E)** and **Figure 4(F)**). 6-OHDA further decreased the
327 levels of HO-1 and NQO-1 in B35 neuroblastoma cells ($P < 0.01$ for HO-1, $P < 0.05$
328 for NQO-1) (**Figure 4(G)** and **Figure 4(H)**). The DF extract at 50 ~ 100 $\mu\text{g/mL}$
329 restored the levels of PI3K and NQO-1 as well as the ratio of *p*-AKT to AKT
330 (especially *p*-AKT (ser) vs AKT) ($P < 0.01$, $P < 0.001$), but only the DF extract at 100
331 $\mu\text{g/mL}$ could restore the levels of HO-1 and ratio of *p*-AKT (thr) to AKT ($P < 0.05$, P
332 < 0.01) (**Figure 4(B-H)**).

333

334 Discussion

335 Gu-Sui-Bu is a common traditional Chinese medicine used to prevent
336 aging-associated disorders, including PD, for centuries. DF is a major resource for
337 Gu-Sui-Bu, and PC is an alternative resource in Taiwan. According to phytochemical
338 reports on DF,^{3, 4, 19} flavonoids and phenylpropanoids are major phytoconstituents of
339 DF. Our data indicate that the DF extract had higher levels of total phenolics and
340 flavonoids (approximately two times) compared with the PC extract. Next, we further
341 compared the DF and PC extract chromatograms and matched them with other
342 reports.¹⁹ The DF extract might contain phenolic acids, dihydroxychromone,
343 epicatechin and naringin. The PC extract might contain epicatechin and naringin.

344 Epicatechin and naringin are co-existing phytoconstituents in the DF and PC extracts;
345 however, the certain phytoconstituent peak zones differ between the DF and PC
346 extracts. The DF extract contained higher levels of naringin (approximately two times)
347 than the PC extract. Hence, we suggest that the DF extract has higher phenolic levels,
348 especially for naringin.

349 These phenolic compounds have been shown to correlate with the plant antioxidant
350 activities.^{17, 22} Moreover, in the pathogenesis of PD, both neurotoxic ROS and highly
351 reactive, redox-cycling DA-derived quinones are formed due to enzymatic breakdown
352 by monoamine oxidase (MAO) or autoxidation of excess cytosolic dopamine.¹⁵ ROS
353 mainly include superoxide anion, H₂O₂ and hydroxyl radical. Superoxide anion is
354 produced in a cell's mitochondrion and has been implicated in the pathophysiology of
355 certain diseases such as PD. H₂O₂ yields the highly reactive hydroxyl radical, which is
356 the most reactive and severely damages adjacent biomolecules, such as
357 polyunsaturated fatty acids.¹¹ Our results also indicate that the DF extract had higher
358 ROS scavenging and lipid peroxidation-inhibiting activities as well as reducing power
359 capacity (approximately two times) compared with the PC extract. Moreover, at the
360 concentrations used in the hydroxyl radical scavenging and lipid
361 peroxidation-inhibiting assays, neither the DF nor the PC extract had the capacity to
362 chelate iron. From the above results, we suggested that the DF or PC extract inhibited
363 lipid peroxidation in brain homogenate systems mainly by terminating oxidative chain
364 reactions through its radical scavenging capacity and reducing power; however,
365 certain reports indicate that the activity of certain antioxidant compounds may
366 correlate with iron-chelation.¹¹ Furthermore, at the concentrations used in the
367 ROS-scavenging activity assays, the DF extract also inhibited *p*-quinone production
368 from 6-OHDA autoxidation in a concentration-dependent manner; this effect was

369 greater than for the PC extract. Based on the above phytochemical and antioxidant
370 results, we suggest that ROS-scavenging activities of the DF or PC extract positively
371 correlate with the levels of all phytochemicals; this relationship is consistent with
372 earlier reports.^{17, 22} The enhanced ROS-scavenging activity of the DF extract
373 compared with the PC extract may be due to the DF extract enrichment phenolic
374 compounds, such as naringin, because their antioxidant activities are consistent with
375 the pharmacological activities of naringin and epicatechin.^{10, 23}

376 Similar to PD pathogenesis, 6-OHDA is a selective dopaminergic neurotoxin that
377 induces PD-like cell or animal models via excessive ROS and *p*-quinone generation
378 during 6-OHDA autoxidation.¹⁵ We further found that, at 50 - 250 $\mu\text{g/mL}$, DF extract
379 increased cell viability against 6-OHDA in a concentration-dependent manner and
380 reversed the 6-OHDA-induced morphological changes in B35 neuroblastoma cells.
381 Naringin is an active DF compound identified in our HPLC results and other reports
382 that also protect against rotenone-induced neuronal damage in SH-SY5Y cells.⁹
383 Therefore, we suggest that the DF extract protect against 6-OHDA-induced neuronal
384 damage in B35 neuroblastoma cells partially via scavenging ROS and inhibiting
385 *p*-quinone. However, intracellular redox imbalance is mainly due to an imbalance
386 between generating and eliminating the free radicals, specifically caused by lower
387 intracellular antioxidant defenses.^{11, 13} Neuronal intracellular antioxidant defenses
388 mainly include several antioxidants and protective enzymes that prevent ROS
389 formation or detoxify ROS.¹⁶ GSH recycling includes GSH and related enzymes, such
390 as glutathione peroxidase (GPx) and GR, and is a major intracellular antioxidant
391 defense. In PD patients, the degree of in symptom severity correlates with
392 intracellular GSH loss in substantia nigra.²⁴ Many oxidants, such as 6-OHDA and
393 H_2O_2 , could deplete the intracellular GSH levels and decrease GPx and GR activation

394 in cell culture and animals.^{21, 25} Our results are consistent with the above reports;^{21, 25}
395 incubation with 50 μ M 6-OHDA in B35 neuroblastoma cells for 24 h decreased the
396 GSH cycle activities and increased the oxidative damage. The DF extract at 100
397 μ g/mL reversed the GSH cycle activities that were decreased by 50 μ M 6-OHDA in
398 B35 neuroblastoma cells, which in turn, decreased the oxidative damage. Hence, we
399 suggest that the DF extract attenuated the 6-OHDA-induced neuronal damage by
400 upregulating the antioxidant status via intracellular GSH regeneration and its radical
401 scavenging activity. In fact, naringin which is a major DF extract constituent also
402 protected against the neuronal damage caused by 3-nitropropionic acid or kainic acid
403 via antioxidant activity and intracellular GSH regeneration.^{7, 8} Certain reports further
404 indicated that naringin and epicatechin have neuroprotective activities against
405 rotenone, aluminum and amyloid β peptide *in vitro* and *in vivo*.^{7-10, 26} Based on the
406 above results, we suggest that DF is a potential medicinal plant that protects against
407 PD in a comparison between two commercial Polydiaceae plants.

408 AKT plays a pivotal role in fundamental cellular functions, such as cell
409 proliferation and survival, by phosphorylating a variety of enzymes, including
410 pro-apoptotic regulators, detoxifying and antioxidant proteins, and transcription
411 factors.²⁷ AKT is mainly activated through phosphorylation of T308 (AKT (thr)) and
412 S473 (AKT (ser)) by receptor tyrosine kinases, G-protein-coupled receptors, mTOR
413 complex 2 (mTORC2), DNA-dependent protein kinase (DNA-PK), and other stimuli
414 that induce phosphatidylinositol 3,4,5 triphosphates (PtdIns(3,4,5)P3) production
415 through PI3K.²⁸ Hence, certain reports indicate that AKT is an important therapeutic
416 target for the treating diabetes, stroke, and neurodegenerative disease.^{27, 28} In this
417 study, we found that treating with 6-OHDA for 24 h decreased the levels of PI3K and
418 AKT phosphorylation, especially at S473, in B35 neuroblastoma cells. Hence,

419 6-OHDA mainly inhibited full activation of AKT via obstructing AKT
420 phosphorylation at S473, which causes neuronal damage. The DF extract increased
421 the PI3K levels and restored AKT phosphorylation. Among the various cytoprotective
422 enzymes modulated by the AKT cascade, HO-1 and NQO-1 play an important role in
423 neuroprotective functions.²⁹ Recent, mounting evidence indicates that a
424 pharmacological inducer of HO-1 expression may maximize the intrinsic antioxidant
425 potential of cells.³⁰ NQO-1 is a key enzyme that detoxifies reactive quinones
426 produced from autoxidation and enzymatic oxidation of dopamine.³¹ Our data also
427 indicate that 6-OHDA decreased the HO-1 and NQO-1 levels in B35 neuroblastoma
428 cells. Hence, our results are consistent with other reports that 6-OHDA decreases the
429 HO-1 and NQO-1 expression via inhibiting phosphorylation of the PI3K/AKT
430 pathway, causing neuronal damage.^{32,33} DF also reversed the HO-1 and NQO-1 levels
431 that were decreased by 6-OHDA. Therefore, we suggest that the DF extract induced
432 AKT phosphorylation and further activated HO-1 and NQO-1 expression to
433 counteract the neurotoxicity and decrease the neuronal damage caused by 6-OHDA in
434 B35 cells.

435

436 **Conclusion**

437 In conclusion, DF extract had the higher phenolic levels, especially for
438 phenylpropanoids, and exhibited the higher radical scavenging potency compared to
439 PC extract. Its antioxidant activity can be correlated with its reducing power, which is
440 not due to iron chelation, and this antioxidant activity depends on the phenolic
441 antioxidants such as naringin and epicatechin.¹⁹ The DF extract has a protective effect
442 against 6-OHDA-induced neuronal damage *in vitro*. Naringin and epicatechin are its
443 major active compounds because naringin and epicatechin can protect against

444 neuronal damage caused by rotenone and amyloid β peptide.^{9,26} This protective
445 mechanism might be related to its radical scavenging capacity and its ability to
446 activate intracellular antioxidant defenses, including GSH recycling as well as HO-1
447 and NQO-1 via the phosphorylation in the PI3K/AKT pathway (**Figure 5**). Hence, we
448 suggest that DF extract has potential therapeutic benefits for treating aging-associated
449 symptoms and neurodegenerative disorders. However, the expressions of detoxifying
450 and antioxidant enzymes such as GSH-related enzymes, HO-1 and NQO-1 are
451 coordinated and induced via a nuclear factor-E2-related factor 2 (Nrf2)-dependent and
452 antioxidant response element (ARE)-mediated mechanism.³⁴ Recent studies have
453 reported that Nrf2 is a master redox regulator that upregulates HO-1 to protect
454 dopaminergic neurons against 6-OHDA-induced neurotoxicity.^{35,36} Studies have also
455 suggested that Nrf2 nuclear translocation requires the activation of several signal
456 transduction pathways, such as PI3K/AKT or the mitogen-activated protein kinase
457 (MAPK) pathways.^{32,34,36} In addition, naringin is a major active compound in DF
458 extract and has also been shown to protect against 3-nitropropionic acid-induced
459 apoptosis via downregulating the pro-apoptotic gene Bax and the upregulating the
460 anti-apoptotic genes Bcl-2 and Bcl-X(L).⁷ The expression of pro-apoptotic genes is
461 also modulated by AKT.^{27,28} Therefore, the anti-apoptotic effects from DF extract and
462 the role of pro-apoptotic genes and Nrf2 translocation mediated by PI3K/AKT in the
463 neuroprotective effects from DF extract must be further investigated.

464

465 **Acknowledgments**

466 We thank the financial support of the National Sciences Council
467 NSC98-2320-B-039-041 MY3, NSC101-2320-B-039-051, NSC
468 101-2120-M-009-008 and NSC102-2320-B-039-037.

469

470 **References**

471

- 472 1. K. C. Wong, W. Y. Pang, X. L. Wang, S. K. Mok, W. P. Lai, H. K. Chow, P.
473 C. Leung, X. S. Yao and M. S. Wong, *Br J Nutr*, 2013, 110, 475-485.
- 474 2. X. F. Huang, S. J. Yuan and C. Yang, *Mol Med Rep*, 2012, 6, 547-552.
- 475 3. X. L. Wang, N. L. Wang, H. Gao, G. Zhang, L. Qin, M. S. Wong and X. S.
476 Yao, *Nat Prod Res*, 2010, 24, 1206-1213.
- 477 4. X. L. Wang, N. L. Wang, Y. Zhang, H. Gao, W. Y. Pang, M. S. Wong, G.
478 Zhang, L. Qin and X. S. Yao, *Chem Pharm Bull (Tokyo)*, 2008, 56, 46-51.
- 479 5. T. Y. Hung, T. L. Chen, M. H. Liao, W. P. Ho, D. Z. Liu, W. C. Chuang and
480 R. M. Chen, *J Ethnopharmacol*, 2010, 131, 70-77.
- 481 6. H. C. Chang, G. J. Huang, D. C. Agrawal, C. L. Kuo, C. R. Wu and H. S.
482 Tsay, *Botanical Studies*, 2007, 48, 397-406.
- 483 7. K. Gopinath, D. Prakash and G. Sudhandiran, *Neurochem Int*, 2011, 59,
484 1066-1073.
- 485 8. M. Golechha, U. Chaudhry, J. Bhatia, D. Saluja and D. S. Arya, *Biol Pharm*
486 *Bull*, 2011, 34, 360-365.
- 487 9. H. J. Kim, J. Y. Song, H. J. Park, H. K. Park, D. H. Yun and J. H. Chung,
488 *Korean J Physiol Pharmacol*, 2009, 13, 281-285.
- 489 10. E. Cuevas, D. Limon, F. Perez-Severiano, A. Diaz, L. Ortega, E. Zenteno and
490 J. Guevara, *Eur J Pharmacol*, 2009, 616, 122-127.
- 491 11. M. Valko, D. Leibfritz, J. Moncol, M. T. Cronin, M. Mazur and J. Telser, *Int J*
492 *Biochem Cell Biol*, 2007, 39, 44-84.
- 493 12. D. Harman, *Ann N Y Acad Sci*, 2006, 1067, 10-21.

- 494 13. D. A. Butterfield and R. Sultana, *Expert Rev Proteomics*, 2008, 5, 157-160.
- 495 14. S. Jana, A. K. Maiti, M. B. Bagh, K. Banerjee, A. Das, A. Roy and S.
496 Chakrabarti, *Brain Res*, 2007, 1139, 195-200.
- 497 15. R. Soto-Otero, E. Mendez-Alvarez, A. Hermida-Ameijeiras, A. M.
498 Munoz-Patino and J. L. Labandeira-Garcia, *J Neurochem*, 2000, 74,
499 1605-1612.
- 500 16. X. L. Chen and C. Kunsch, *Curr Pharm Des*, 2004, 10, 879-891.
- 501 17. C. R. Wu, W. H. Lin, Y. C. Hseu, J. C. Lien, Y. T. Lin, T. P. Kuo and H.
502 Ching, *Food Chem*, 2011, 127, 564-571.
- 503 18. L. R. Fukumoto and G. Mazza, *J Agric Food Chem*, 2000, 48, 3597-3604.
- 504 19. H. Liu, S. Zou, Y. Qi, Y. Zhu, X. Li and B. Zhang, *J Nat Med*, 2012, 66,
505 413-419.
- 506 20. C. Sachs and G. Jonsson, *Biochem Pharmacol*, 1975, 24, 1-8.
- 507 21. H. Y. Ju, S. C. Chen, K. J. Wu, H. C. Kuo, Y. C. Hseu, H. Ching and C. R.
508 Wu, *Food Chem Toxicol*, 2012, 50, 492-502.
- 509 22. F. Zhu, Y. Z. Cai, M. Sun, J. Ke, D. Lu and H. Corke, *J Agric Food Chem*,
510 2009, 57, 6082-6089.
- 511 23. M. Cavia-Saiz, M. D. Busto, M. C. Pilar-Izquierdo, N. Ortega, M.
512 Perez-Mateos and P. Muniz, *J Sci Food Agric*, 2010, 90, 1238-1244.
- 513 24. P. Riederer, E. Sofic, W. D. Rausch, B. Schmidt, G. P. Reynolds, K. Jellinger
514 and M. B. Youdim, *J Neurochem*, 1989, 52, 515-520.
- 515 25. J. H. Chen, H. P. Ou, C. Y. Lin, F. J. Lin, C. R. Wu, S. W. Chang and C. W.
516 Tsai, *Chem Res Toxicol*, 2012, 25, 1893-1901.
- 517 26. H. J. Heo and C. Y. Lee, *J Agric Food Chem*, 2005, 53, 1445-1448.
- 518 27. Y. Liao and M. C. Hung, *Am J Transl Res*, 2010, 2, 19-42.

- 519 28. B. A. Hemmings and D. F. Restuccia, *Cold Spring Harb Perspect Biol*, 2012,
520 4, a011189.
- 521 29. A. Jazwa and A. Cuadrado, *Curr Drug Targets*, 2010, 11, 1517-1531.
- 522 30. X. Hu, J. Wang and H. Jiang, *Int J Cardiol*, 2013, 167, 587-588.
- 523 31. Z. Jia, H. Zhu, H. P. Misra and Y. Li, *Brain Res*, 2008, 1197, 159-169.
- 524 32. S. H. Kwon, S. I. Hong, Y. H. Jung, M. J. Kim, S. Y. Kim, H. C. Kim, S. Y.
525 Lee and C. G. Jang, *Food Chem Toxicol*, 2012, 50, 797-807.
- 526 33. C. Deng, R. Tao, S. Z. Yu and H. Jin, *Mol Med Rep*, 2012, 5, 847-851.
- 527 34. Q. Zhang, J. Pi, C. G. Woods and M. E. Andersen, *Toxicol Appl Pharmacol*,
528 2010, 244, 84-97.
- 529 35. H. Oh, J. Hur, G. Park, H. G. Kim, Y. O. Kim and M. S. Oh, *Phytother Res*,
530 2013, 27, 1012-1017.
- 531 36. Y. P. Hwang and H. G. Jeong, *Toxicol Appl Pharmacol*, 2010, 242, 18-28.
- 532
- 533

Table 1. The phytoconstituents of aqueous extracts of Polydiaceae plants.

Samples	Total phenolics (mg of catechin / g)	Flavonols (mg of quercetin / g)	Phenylpropanoids (mg of verbascoside / g)	Anthocyanidin (mg of cyanidin / g)	Epicatechin (mg / g)	Naringin (mg / g)
<i>Drynaria fortunei</i>	268.41 ± 4.41	13.67 ± 0.26	21.05 ± 1.04	2.07 ± 0.04	1.00 ± 0.02	26.23 ± 0.34
<i>Pseudodrynaria coronans</i>	130.10 ± 0.25	7.41 ± 0.10	4.50 ± 0.12	1.22 ± 0.04	1.46 ± 0.08	10.27 ± 0.88

Data were expressed as mean ± SD ($n=3$).

Table 2. ROS scavenging activities of aqueous extracts of Polydiaceae plants.

Samples	O ₂ [•] scavenging (U of SOD / mg)	H ₂ O ₂ scavenging (μmol of trolox / g)	OH [•] scavenging (mg of quercetin / g)	IC ₅₀ of lipid peroxidation (mg / mL)	Reducing power (μmol of trolox / g)
<i>Drynaria fortunei</i>	11.46 ± 0.31	927.57 ± 7.61	14.95 ± 0.31	32.43 ± 0.84	1034.65 ± 21.44
<i>Pseudodrynaria coronans</i>	9.43 ± 0.81	582.60 ± 9.49	4.40 ± 1.46	117.99 ± 10.38	622.64 ± 14.81

Data were expressed as mean ± SD (*n*=3).

Table 3. Effects of aqueous extract of *Drynaria fortunei* (DF) on antioxidant makers and MDA levels in B35 Cells exposed to 50 μ M 6-OHDA

Samples	GSH (pmol/mg of protein)	GR (mU/mg of protein)	GPx (mU/mg of protein)	MDA (nmol/mg of protein)
Control	6.77 \pm 0.21**	15.31 \pm 0.65**	143.52 \pm 8.27**	7.67 \pm 0.33**
6-OHDA	3.08 \pm 0.19	9.83 \pm 0.38	76.24 \pm 7.92	16.23 \pm 0.97
DF 10 μ g/mL + 6-OHDA	3.15 \pm 0.13	10.37 \pm 0.52	81.46 \pm 6.12	14.76 \pm 1.08
DF 50 μ g/mL + 6-OHDA	3.21 \pm 0.17	10.85 \pm 0.71	87.37 \pm 9.16	14.12 \pm 0.84
DF 100 μ g/mL + 6-OHDA	4.47 \pm 0.23*	13.74 \pm 0.47*	121.45 \pm 7.53*	9.69 \pm 0.43*

B35 cells were treated with the above samples plus 50 μ M 6-OHDA. Data are expressed as mean \pm SEM ($n = 4$). * $p < 0.05$, ** $p < 0.01$ as compared to the 6-OHDA group.




Figure 1. HPLC chromatograms of *Drynaria fortunei* (DF) or *Pseudodrynaria coronans* (PC) extract at 280 nm. Trace: (A) Standard, (B) DF at 5 mg/mL, (C) PC at 10 mg/mL.
240x141mm (150 x 150 DPI)




Figure 2. Effect of *Drynaria fortunei* (DF) or *Pseudodrynaria coronans* (PC) extract on p-quinolone production from 6-hydroxydopamine (6-OHDA) autoxidation. Data are expressed as mean \pm SEM ($n = 3$). * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$, compared with VEH group.
435x305mm (300 x 300 DPI)




Figure 3. Effect of *Drynaria fortunei* (DF) extract on 6-hydroxydopamine (6-OHDA)-induced toxicology in B35 cells. Data are expressed as mean \pm SEM ($n = 4$). (A) Cell viability was measured by MTT assay. (B) Cell morphology was visualized by a phase-contrast microscope (100 \times). (B)-a, control; (B)-b, B35 cells exposed to 50 μ M 6-OHDA; (B)-c, B35 cells treated with 100 μ g/mL of DF extract plus 50 μ M 6-OHDA; (B)-d, B35 cells treated with 100 μ g/mL of PC extract plus 50 μ M 6-OHDA. ** $p < 0.01$, *** $p < 0.001$, compared with 6-OHDA/VEH group.
442x249mm (150 x 150 DPI)




Figure 4. Effect of *Drynaria fortunei* (DF) on 6-hydroxydopamine (6-OHDA)-induced alteration of PI3-K and AKT activation in B35 cells. (A) Protein was determined by immunoblot assay, (B) Levels of PI3-K expression, (C) Levels of AKT expression, (D) Ratio of p-AKT (thr) / AKT, (E) Ratio of p-AKT (ser) / AKT, (F) Levels of HO-1 expression, (G) Levels of NQO-1 expression. Data are expressed as mean \pm SEM (n = 3). * p < 0.05, ** p < 0.01, *** p < 0.001, compared with 6-OHDA group.
233x184mm (150 x 150 DPI)




Figure 5. The biological action of *Drynaria fortunei* (DF) as a potential antioxidant and protective plant against oxidative stress caused by 6-hydroxydopamine (6-OHDA). Prohibition sign indicates that the inhibitory effect of *Drynaria fortunei*.
126x126mm (150 x 150 DPI)